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Objectives: An early economic evaluation to inform the translation into clinical practice of a 
spectroscopic liquid biopsy for the detection of brain cancer. Two specific aims are: [1] to 
update an existing economic model with results from a prospective study of diagnostic 
accuracy, and [2] explore the potential of brain tumour type predictions to affect patient 
outcomes and healthcare costs. 
Methods: A cost-effectiveness analysis from a UK NHS perspective of use of spectroscopic 
liquid biopsy in primary and secondary care settings, as well as a cost-consequences analysis 
of the addition of tumour type predictions were conducted. Decision tree models were 
constructed to represent simplified diagnostic pathways. Test diagnostic accuracy parameters 
were based on a prospective validation study. Four price points (GBP 50-200, EUR 57-228) 
for the test were considered. 
Results: In both settings use of liquid biopsy produced QALY gains. In primary care, at test 
costs below GBP 100 (EUR 114) testing was cost saving. At GBP 100 (EUR 114) per test the 
ICER was GBP 13,279 (EUR 15,145) while at GBP 200 (EUR 228) the ICER was GBP 
78,300 (EUR 89,301). In secondary care, the ICER ranges from GBP 11,360 (EUR 12,956) 
to GBP 43,870 (EUR 50,034) across the range of test costs.  . 
Conclusions: Results demonstrate potential for the technology to be cost-effective in both 
primary and secondary care settings. Additional studies of test use in routine primary care 
practice is needed to resolve the remaining issues of uncertainty - prevalence in this patient 
population and referral behaviour. 
Keywords: ‘Spectroscopy, Fourier Transform Infrared’,’ Brain Neoplasms’, ‘Economic 
Model’  
Introduction 
 
Brain tumours have among the worst prognosis of all cancer types. In England, the 1-year 
survival rate is 40 percent while the 5-year survival rate is as low as 15 percent [1]. This, at 
least in part, may relate to late presentation and diagnosis. The symptoms experienced by 
patients with a brain tumour can be vague and non-specific and as such have only a poor 
predictive value from a diagnostic perspective [2][3]. Headache, the most common symptom 
of brain tumours in adults, also occurs in 4.4 percent of all primary care consultations but has 
a positive predictive value of only  0.09 percent [2]. A study of symptom-based referral 
pathways for suspected brain tumour reported a positive predictive value (PPV) of 2.8 
percent  for severe red flag symptoms in terms of detecting a brain tumour on subsequent 
brain imaging [4]. There is clinical need for new tests to support brain tumour diagnosis that 
both reduce diagnostic delay and reduce unnecessary imaging. 
The liquid biopsy proposed here is based on Fourier-transform infrared (FTIR) spectroscopy 
applied to serum from a standard blood sample. The spectral data is collected and analysed 
using pattern recognition and machine learning algorithms to detect disease-specific 
signatures [5]. Liquid biopsy results predict presence or absence of cancer and may also 
suggest cancer type. 
The test was developed using data from 433 patient blood samples, including those with and 
without brain tumours. Using a 5-fold cross-validation strategy to assess accuracy in the 
development data a sensitivity of 92.8 percent and specificity of 91.5 percent was reported 
[6]. This result was further validated in a larger retrospective cohort of 724 patients with 
sensitivity of 93.2 percent and specificity of 92.8 percent reported [5]. 
Translation of entirely new diagnostic technologies to the clinic is highly challenging with 
complex and internationally varying regulatory and reimbursement decision making [7]. 
Early economic evaluation has been proposed as a method to guide the development of 
medical tests from the lab to the clinic [8]. By obtaining estimates of cost-effectiveness 
before the final stage clinical research or commercialisation, efficiency in translation can be 
improved. Clinical applications that are unlikely to be able to demonstrate cost-effectiveness 
can be halted while more promising applications can be progressed [9]. 
In an early economic evaluation [10], we mapped a clinical pathway integrating 
spectroscopic liquid biopsy as a triage test in both primary and secondary care. Patients 
would be tested with a liquid biopsy prior to referral for brain imaging studies, those testing 
positive would be prioritised to urgent imaging (within 1 week) while those testing negative 
would have standard referral (around 4 weeks) or follow-up without further investigation. It 
is expected that all patients seen in secondary care would ultimately receive imaging tests 
while many in primary care could forgo imaging for the time being if they received a 
negative liquid biopsy result. Under current standard of care all patients would be referred for 
brain imaging via either specialist or open-access services.  
Cost-effectiveness analysis results suggested the potential for the technology to be cost-
effective subject to confirmation of diagnostic accuracy and test cost. The next stage in 
translation was identified to be a prospective validation study of test accuracy with patient 
blood samples gathered prior to diagnosis and treatment. This study required symptomatic 
patients only, without ‘healthy’ controls, as would be the case in the proposed clinical setting. 
A study of this type has now reached a pre-planned interim analysis [Brennan et al, under 
review], necessitating an update of the economic evaluation to inform the next stage of 
development. A cohort study design was used, recruiting from high-risk settings in secondary 
care. At the pre-planned interim analysis when recruitment had reached 400 patients the 
prospective validation study reported test sensitivity of 81 percent and specificity of 80 
percent. This iteration of the early economic evaluation updates the cost-effectiveness 
analysis with these estimates to help inform the next stage of translation of the technology. 
We also examine a new extension of the clinical pathway. Recent research has established 
that there is scope to differentiate between brain tumour types as part of the same liquid 
biopsy based on FTIR serum spectroscopy [11]. The ability to provide a prediction of the 
tumour type may have additional diagnostic value. This could be particularly beneficial in 
cases when brain imaging is inconclusive for the tumour type. For example, the aggressive 
grade IV glioma, glioblastoma (GBM), may have similar radiological appearance with 
primary central nervous system lymphoma (PCNSL) and brain metastases, but all have very 
different treatment pathways [12,13]. This issue was highlighted as an important problem by 
clinical experts in focus groups [10]. Therefore, in this study we sought to explore the impact 
of providing tumour type classification on healthcare costs and patient management pathways 
through an extension of the cost-effectiveness model. 
This study aims to inform development of the test in two ways: 
[1] Estimate the cost-effectiveness of the spectroscopic liquid biopsy in both primary and 
secondary care in the UK NHS based on prospective diagnostic performance. 
[2] Estimate the cost-consequences of providing additional tumour type predictions to 
clinicians at the point of confirmation of brain tumour diagnosis by imaging. 
Methods 
 
A cost-effectiveness analysis was conducted from a UK NHS perspective to evaluate the 
effect of the addition of triage blood test for brain cancer to standard diagnostic practice. Life 
years (LY), quality-adjusted life years (QALY) and healthcare costs were estimated for both 
current standard practice and practice with the addition of the test. The time horizon of the 
analysis is two years. Unit costs used a price year of 2017/2018. Costs in GBP were 
converted to EUR at a rate of 1.1405 [14].  
A cost-consequences analysis was conducted to explore the consequences of providing 
additional information of the probability of tumour types. The analysis applies only to 
patients with a tumour confirmed by imaging. Healthcare costs, probability of surgery, and 
probability of biopsy were compared between standard practice and practice when predicted 
probability of different tumour types is available. Surgery is both the major resource item and 
a significant source of possible harm for patients [15]. Reducing unnecessary surgery is the 
principal outcome of interest in addition to total healthcare costs. 
A decision-analytic model was constructed to represent the alternative clinical pathways for 
suspected brain tumour patients with or without a triage blood test available [10]. A decision 
tree structure was selected because this can feasibly represent the alternative diagnostic 
pathways and outcomes over a short time horizon. A two year time horizon was selected 
because of the short duration of survival in this patient group, less than 20 percent are 
expected to survive beyond 2 years [16]. The model structure is shown in Figure 1. The 
figure shows the decision tree for the diagnostic pathway using a spectroscopic liquid biopsy. 
Without the spectroscopic liquid biopsy all patients in both primary and secondary care 
receive a standard referral to imaging. A positive liquid biopsy test provides the opportunity 
for a fast-track referral and consequently earlier diagnosis. . The clinical pathways of patients 
presenting in primary and secondary care were evaluated separately. A key difference is that 
in primary care a proportion of patients who have tested negative may forgo imaging referral 
while in secondary all will receive at least a standard imaging referral. This feature also 
means that there may be harms from false negative results in primary care leading to a longer 
time-to-diagnosis. Prevalence of brain tumours of patients presenting in secondary care (3 
percent) is higher than in primary care (1 percent)[10]. Prevalence in each setting was 
determined in the prior evaluation based on evidence from observational data and clinical 
expert opinion on the population that would be selected for testing in practice [10]. LY and 
QALY gains are driven by a reduction in delays to diagnosis for those patients with a brain 
tumour, leading to increased expected survival time, explained in more detail in [10]. The 
selected prevalence and test accuracy in the base case imply a false negative rate per 10,000 
patients tested of 57 in secondary care and 19 in primary care, with a corresponding false 
positive rate of 1,940 in secondary care and 1,980 in primary care. 
An extension of this decision tree was constructed for tumour type information (Figure 1). 
Tumour type classification probabilities allow varying diagnostic protocols for patients that 
test positive and have a tumour confirmed by imaging study (i.e. true positive for a brain 
tumour for the serum spectroscopy test). Three possible management routes were included in 
the model. Those who are predicted to have high grade glioma/GBM go directly to surgery. 
A prediction of primary central nervous system lymphoma (PCNSL) leads to a biopsy and 
medical therapy. Predicted metastatic cancer of unknown origin leads to further imaging 
investigation (with avoidance of brain surgery or biopsy in most cases). Under standard care 
all these patients would be presumed to have a GBM and directed to surgical resection, with 
alternative diagnosis happening during or after the surgery.     
Unit cost parameters are listed in Supplementary Table 1,Decision tree parameters are listed 
in Supplementary Table 2. Outcomes (healthcare costs, remaining LY and QALYs) for each 
leaf of the decision tree were specified as in [10]. Survival, quality of life and cost parameters 
for the cost-consequences analysis are displayed in Supplementary Table 3. Prices for 
imaging studies and surgery were sourced from NHS reference costs (2017-2018). 
Cost-effectiveness results for the base case analysis were summarized by the incremental 
cost-effectiveness ratio (ICER) at four selected spectroscopic liquid biopsy price points. Key 
parameters of prevalence and effect of delay on survival were varied in one-way sensitivity 
analysis (OWSA), these are presented on a cost-effectiveness plane. OWSA of test sensitivity 
and specificity is available in [10]. A probabilistic sensitivity analysis (PSA) was conducted 
to understand uncertainty across all key model parameters arising from sampling uncertainty. 
The PSA results are reported on a cost-effectiveness plane and as a cost-effectiveness 
acceptability curve (CEAC). 
Results 
 
In the base case of the cost-effectiveness analysis (Table 1), updated with prospective 
validation results, spectroscopic liquid biopsy testing would lead to a gain of 15.4 QALYs per 
10,000 patients in primary care use and 65.4 QALYs per 10,000 patients in secondary care 
use. In primary care, at test costs below GBP 100 (EUR 114) testing was cost saving. At GBP 
100 (EUR 114) per test the ICER was GBP 13,279 (EUR 15,145) while at GBP 200 (EUR 
228) the ICER was GBP 78,300 (EUR 89,301). In secondary care, the ICER ranges from 
GBP 11,360 (EUR 12,956) to GBP 43,870 (EUR 50,034) across the range of test costs. The 
results of the previously published, first iteration of the early evaluation using retrospective 
data are available in Supplementary Table 4 to see the effect of the attenuation of diagnostic 
performance on cost-effectiveness.  
OWSA on prevalence (Supplementary Figure 1) and HR for delay to diagnosis 
(Supplementary Figure 2) show that these parameters are highly influential. Both are strong 
determinants of the QALY difference between diagnostic strategies and therefore influence 
cost-effectiveness. For example, at a test cost of GBP 100 (EUR 144) if prevalence were 0.5 
percent instead of 1 percent in primary care then the ICER would be >GBP 20,000 (EUR 
22,810) and the technology may not be considered cost-effective. 
The CEAC plot (Figure 2) demonstrates that at a test cost of GBP 100 (EUR 114) there is 
approximately a 75% probability of being cost-effective in primary care and a 50% 
probability of being cost-effective in secondary care at a ICER threshold of GBP 20,000 
(EUR 22,810). At the lower end of the range of test costs (GBP 50, EUR 57) testing is highly 
likely to be cost-effective at any ICER threshold in primary care and at thresholds above GBP 
15,000 (EUR 17,108) in secondary care. Supplementary Figure 3 shows the PSA results on 
the cost-effectiveness plane. This highlights the importance of uncertainty about effectiveness 
in both scenarios and uncertainty about costs for the primary care scenario only. 
The cost-consequences analysis results of providing tumour type information are reported in 
Table 2. Tumour type predictions have the potential to reduce surgeries by approximately 8 
per 100 brain tumour cases. The additional healthcare cost savings are approximately GBP 
58,000 (EUR 66,149) per 100 cases. These estimates are sensitive to the relative frequency of 
GBM, PCNSL and metastatic disease in the patient population (Supplementary Figure 4). 
There are significantly larger cost-savings possible when other tumour types are relatively 
more prevalent among cases compared to GBM. The total budget impact for the NHS in 
England and Wales if this was rolled-out nationally would be approximately GBP 1.3-2 
million (EUR 1.5-2.3 million) assuming 50-80% of the 4,500 malignant brain tumours 
diagnosed each year [17] had received testing. 
Discussion 
A prospective study of diagnostic accuracy has brought a spectroscopic liquid biopsy for 
brain cancer one step closer to being ready for clinical use. The updated cost-effectiveness 
results reported here demonstrate potential for the technology to be cost-effective in both 
primary and secondary care settings. Compared to the base case result in the previous 
iteration of the evaluation, effectiveness is reduced due to the attenuation of diagnostic 
accuracy in the prospective data. This iteration of the early economic evaluation also 
extended the clinical pathway to include a new feature of the technology - classification of 
tumour type.  The cost-consequences analysis demonstrated some additional utility and cost-
savings from providing tumour type classification probabilities.  
New evidence in relation to diagnostic accuracy may emerge as more data is collected in 
ongoing studies. This can then be used to update the economic evaluation in a further 
iteration. Machine learning based classification systems can require large numbers of 
observations to achieve optimal performance therefore it is possible that improvements in 
diagnostic accuracy may occur after more training data is collected. Prospective data from 
primary care would also be useful to determine if diagnostic accuracy is the same in this 
setting and alleviate concerns about possible spectrum bias.  
This economic evaluation provides support for the continued development of a serum 
spectroscopy test for brain tumours. Remaining issues relate to the feasibility of integrating 
the test into routine practice. An important aspect of this is understanding how patient 
selection by clinicians would influence disease prevalence in the tested population. This was 
highlighted as an important parameter in the sensitivity analysis. Another issue, identified in 
the previous iteration of early evaluation [10], is to what extent brain imaging studies would 
actually be reduced in primary care, i.e. what proportion of test negative patients would not 
be subsequently referred to imaging.  
The major limitations of this analysis are related to the lack of direct evidence of how 
alternative diagnostic pathways will influence patient survival and quality of life. In the 
absence of this data we have relied on extrapolation from observational data. While this data 
is available from a cohort studies [18,19], treating the association between time to treatment 
and survival as causal requires strong assumptions.  
An open question is whether or not a randomised trial of alternative diagnostic strategies (test 
vs no test) is required to demonstrate patient benefit for this technology. Whether a 
randomised trial(s) is desirable or not can be considered within existing frameworks [20]. 
This requires the judgement of all relevant stakeholders regarding the feasibility of a trial as 
well as the validity of assuming survival and quality of life benefits of early diagnosis. While 
a randomised trial offers the best possible evidence on which to base an adoption decision, 
the scale of the trial that would be required may prove prohibitively expensive to undertake, 
and it is well recognised that randomised trials for diagnostic tests are often unfeasible [21]. 
The vast majority of tests in clinical practice today do not have evidence of patient benefit 
from a randomised trial. A feasible solution in this case may be a post-marketing study, 
forgoing randomisation in favour of a cohort study design. It has been suggested that an 
observational study assessing time to diagnosis and treatment may be optimal for a triage test 
when a randomised design is infeasible [20]. A study of the hypothetical clinical utility of test 
results using a questionnaire survey among primary care clinicians may be a useful preceding 
step. These types of studies could address the two key remaining areas of uncertainty; 
prevalence in the referred population and clinical decision making in response to negative test 
results. Clear benchmarks for clinical utility could be determined and a risk sharing model for 
reimbursement [22] may be useful to explore. Determining the optimal design of future 
studies requires a full exposition and consultation with stakeholders, beyond the scope of this 
early economic evaluation. 
Translation of the economic model to other countries or health systems will also require 
refining the above parameters and may need further development of the economic model. In 
the preceding evaluation the USA healthcare system was considered using Medicare unit 
prices [10]. We now believe that differences between UK and USA health systems may 
necessitate a different model structure. Validation or adaption of the diagnostic and clinical 
pathway represented in the model to health systems in the United States is part of ongoing 
research. 
Early economic evaluation has been useful in guiding the development of this liquid biopsy 
test for brain tumours. Making an early assessment of both costs and consequences of other 
novel tests in the domain of liquid biopsies for cancer may improve the focus of clinical 
research efforts in this area. Ultimately, comparative cost-effectiveness analysis with both 
existing diagnostic pathways and all potential new alternatives would be most useful for 
clinicians, patients and health system decision makers. 
A logical next stage of development for spectroscopic liquid biopsy for brain tumours is a 
large scale, pragmatic programme of test use in routine primary care practice. Additional 
studies in this setting are needed to resolve the remaining issues of uncertainty - prevalence in 
this patient population and referral behaviour -  and would demonstrate feasibility in real-
world clinical practice. 
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Tables 
Table 1 - Cost-effectiveness analysis base case results 
 
Primary 
  
Secondary 
  
Serum 
spectroscopy 
cost (GBP) 
∆QALY 
per 
10,000 
referred 
∆Cost 
per 10,000 
referred 
GBP 
(EUR) 
ICER 
GBP 
(EUR) 
 
∆QALY 
per 10,000 
referred 
∆Cost 
per 10,000 
referred 
GBP 
(EUR) 
ICER 
GBP 
(EUR) 
 
50 15.38 -295,780 
(-337,337) 
Dominates*  
(-19,232) 
(-21,934) 
46.14 524,130 
(597,770) 
11,360 
(12,956) 
75 15.38 -45,780 
(-52,212) 
Dominates  
(-2,977) 
(-3,395) 
46.14 774,130 
(882,895) 
16,778 
(19,135) 
100 15.38 204,220 
(232,913) 
13,279 
(15,148) 
46.14 1,024,130 
(1,168,020) 
22,197 
(25,316) 
200 15.38 1,204,220 
(1,373,413) 
78,300 
(89,301) 
46.14 2,024,130 
(2,308,520) 
43,870 
(50,034) 
*More effective and less expensive 
Table 2 Cost-consequences per 100 cases with and without type information 
Category Liquid biopsy sub-
type information 
available 
Standard Care Difference 
Surgical resection 100 92.1 -7.9 
Biopsy 2 4 2 
CT full body 0 7 7 
Total costs (GBP) 796,876 
(EUR 908,837) 
738,970 
(EUR 842,795) 
-57,906 
(EUR -66,042) 
 
 
  
Figure Legends 
Figure 1 - Decision Tree Model and Extension 
 
Figure 1 Legend: Outcomes 1: LY 0.80, QALY 0.71. Outcomes 2: LY 2, QALY 2. Outcomes 
3: LY 0.58, QALY 0.52. Abbreviations: GBM Glioblastoma, PCNSL Primary Central 
Nervous System Lymphoma 
 
  
Figure 2 - Cost-effectiveness acceptability curve, primary care and secondary care scenarios 
at GBP 50 (EUR 57) and GBP 100 (EUR 114) test cost 
 
 
